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Solid-phase synthesis of BRL 49653
Obesity is an increasingly common disease in the western world and incidence has been
associated with a range of other diseases including hypertension, atherosclerosis and type II
(non-insulin dependent) diabetes. However, little is known about the proteins that mediate
gene control of lipid metabolism. One possible clue is the class of peroxisome proliferator
activated receptors (PPARs), a family of nuclear receptors that respond to long-chain fatty
acids and prostaglandins and that have been a subject of this column in previous months.
Further study of this family of receptors might yield vital clues in the understanding of the
signalling pathways that regulate energy balance.
One agent known to bind to the mPPARγ is the antidiabetic thiazoldinedione, BRL 49653 (1),
and it was judged that a common route to the synthesis of analogues might help clarify an
understanding of the role of PPARs. A recent paper describes the solid-phase synthesis of
BRL 49653 and indicates how this route might be used for the preparation of other analogues
(K.M. Brummond and J. Lu, J. Org. Chem., 64, (1999), 1723-1726).
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The key to the synthesis was the discovery that the 2,4-thiazolidinedione moiety could be
attached to polystyrene support through the 3,5-dimethoxyphenol linker (2), thus allowing
final cleavage under mild acidic conditions. The molecule was built up by Knoevenagel
condensation, Mitsunobu chemistry, and nucleophilic aromatic substitution. The authors are
currently using this synthetic route in the preparation of structurally diversified analogues of
BRL 49653.
--------------------------------------------------------------------------------------------------------------
Novel protein kinase inhibitors
Calcium is key to the regulation of large diversity of cellular functions, often through a calcium
receptor protein such as the well characterised calmodulin (CaM). However, the ubiquity with
which CaM functions as a calcium receptor makes it an unattractive molecular target for drug
design. A recent paper describes the use of combinatorial chemistry to optimise peptide
inhibitors of a protein kinase that clearly do not work through the calcium receptor (T.J.
Lukas et al., J. Med. Chem., (1999), 42, 910-919).
Myosin light chain kinase (MLCK) possesses a CaM calcium binding region, but functional
genomics studies were used to identify a lead peptide inhibitor based on a core autoinhibitory
sequence. The lead peptide, (Arg-Lys-Lys-Tyr-Met-Ala-Arg-Arg-Lys-NH2) with an IC50 value
of 1.2 µM, was modified using the ‘mix and split’ library method. As basic amino acid residues
were important for selective inhibition of MLCK, these were held constant and the library
focused on variation of the central three residues. Using 18 amino acid residues, the first round
of synthesis generated 18 pools each of 5832 possible peptide sequences. Recursive
deconvolution eventually revealed a peptide sequence (Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-
Lys-NH2) with an IC50 value of 50nM, and 4000-fold selectivity over CaM kinase II, thus
demonstrating that this inhibitor has little affinity for the calcium-binding protein. Such
inhibitors add to the tools available for the deconvolution of complex signal transduction
pathways.
--------------------------------------------------------------------------------------------------------------
Inhibition of Ras farnesylation
Much is known about the structure and function of Ras proteins. Whilst they have a central
function in normal cell processes, point mutations activate the oncogenic potential of Ras
genes. The proteins undergo a series of post-translational modifications at their carboxy
termini, including farnesylation and subsequent terminal tripeptide cleavage. Oncogenic Ras
proteins have been considered as reasonable targets for the discovery of cancer therapeutics,
often using the inhibition of farnesyl transferase as a pharmacological mechanism. An
alternative strategy of finding compounds that bind to the carboxy terminus of the Ras protein
has been described (D.L. Dong et al., Chem. Biol., (1999), 6, 133-141).
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A combinatorial library of molecular forceps consisting of short peptide chains attached to
both rigid (chenodeoxycholic acid) and flexible (lysine) scaffolds were prepared using a set of
15 L- and D-amino acids. The total library size of 151,875 molecules were prepared on
TentaGel resin using mix and split synthesis with the synthetic history of each bead being
recorded using molecular catechol tags. Analysis of beads that bound to the Ras carboxy-
terminal decapeptide revealed a number of active structures. Of these, the compound (3)
bound to the carboxy terminus of Ras and inhibited the farnesylation with an IC50 value of
100µM.
